

Federal securities laws, such as Rules 10b-5 and 15c2-11 of the Securities Exchange Act of 1934 (“Exchange Act”) as well as Rule 144 of the Securities Act of 1933 (“Securities Act”), and state Blue Sky laws, require issuers to provide *adequate current information* to the public markets. With a view to encouraging compliance with these laws, OTC Markets Group has created these OTC Pink Basic Disclosure Guidelines. We use the basic disclosure information provided by OTC Pink companies under these guidelines to designate the appropriate tier in the OTC Pink marketplace: Current, Limited or No Information. OTC Markets Group may require companies with securities designated as Caveat Emptor to make additional disclosures in order to qualify for OTC Pink Current Information tier.

### **Qualifications for the OTC Pink - Current Information Tier**

Companies that make the information described below publicly available on a timely basis (90 days after fiscal year end for Annual Reports; 45 days after each fiscal quarter end for Quarterly Reports) qualify for the Current Information Tier. Financial reports must be prepared according to U.S. GAAP or IFRS, but are *not required to be audited* to qualify for the OTC Pink Current Information tier.

#### **Initial Qualification:**

1. Subscribe to the [OTC Disclosure & News Service](#) on [www.OTCIQ.com](http://www.OTCIQ.com) to publish your financial reports and material news.
2. Create the following documents, save them in PDF format and upload them via [www.OTCIQ.com](http://www.OTCIQ.com):
  - Annual Financial statements (Document must include: Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements) for the previous two fiscal years. If these reports are audited, please attach the audit letter from the [PCAOB](#) registered audit firm. Each year’s Annual Financial statements should be posted separately under the report type “Annual Report” in OTCIQ.
  - Any subsequent Quarterly Reports since the most recent Annual Report.
  - The most recent fiscal period end report should also include information in accordance with these OTC Pink Basic Disclosure Guidelines; use the fillable form beginning on page 3.
3. If financial reports are not audited by a [PCAOB](#) registered audit firm:
  - Submit a signed Attorney Letter Agreement (first two pages of the [Attorney Letter Guidelines](#)).
  - After following the appropriate procedures with a qualified attorney, upload an Attorney Letter complying with [Attorney Letter Guidelines](#) through your [otciq.com](http://otciq.com) account.

#### **Ongoing Qualification:**

1. **For each Fiscal Quarter End**, upload a Quarterly Report via [www.OTCIQ.com](http://www.OTCIQ.com) within **45 days** of the quarter end. (A separate quarterly report is not required for the 4<sup>th</sup> quarter.) The Quarterly Report should include:
  - Information in accordance with these OTC Pink Basic Disclosure Guidelines -- use the fillable form beginning on page 3.
  - Quarterly financial statements (Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements).
  - No Audit Letter or Attorney Letter is required.
2. **For each Fiscal Year End**, upload an Annual Report within **90 days** of the fiscal year end. The Annual Report should include:
  - Information in accordance with these OTC Pink Basic Disclosure Guidelines -- use the fillable form beginning on page 3.
  - Annual financial statements (Balance Sheet, Income Statement, Statement of Cash Flows, Notes to Financial Statements, and Audit Letter, if the financial statements are audited).
3. If financial reports are not audited by a PCAOB registered audit firm, upload an Attorney Letter via [www.OTCIQ.com](http://www.OTCIQ.com) complying with the [Attorney Letter Guidelines](#) within **120 days** of the fiscal year end.

### **Qualifications for the OTC Pink - Limited Information Tier**

Companies that make the information described below publicly available within the prior 6 months qualify for the Limited Information Tier.

1. Subscribe to the [OTC Disclosure & News Service](http://www.OTCIQ.com) on [www.OTCIQ.com](http://www.OTCIQ.com) to publish your financial reports and material news.
2. Create a Quarterly Report or Annual Report for a fiscal period ended within the previous 6 months, save it in PDF format and upload it via [www.OTCIQ.com](http://www.OTCIQ.com). The Quarterly Report or Annual Report includes:
  - Balance Sheet, Income Statement, and Total Number of Issued and Outstanding Shares. Financial statements must be prepared in accordance with US GAAP, but are not required to be audited. (Please note that Cash Flow Statements are not required to qualify for the Limited Information tier; however, unless the financial statements include a Cash Flow Statement, no financial data will be included in the OTC Financials Data Service, which distributes company financial data to online investor portals and makes the data available on your company's Financials tab on [www.otcmarkets.com](http://www.otcmarkets.com))
  - A company in the Limited Information tier, may, but is not required to, include information in accordance with these OTC Pink Basic Disclosure Guidelines using the fillable form beginning on page 3.

### **Current Reporting of Material Corporate Events**

OTC Markets Group encourages companies to make public disclosure available regarding corporate events that may be material to the issuer and its securities. Persons with knowledge of such events would be considered to be in possession of material nonpublic information and may not buy or sell the issuer's securities until or unless such information is made public. If not included in the issuer's previous public disclosure documents or if any of the following events occur after the publication of such disclosure documents, the issuer shall publicly disclose such events by disseminating a news release within 4 business days following their occurrence, and posting such news release through the OTC Disclosure & News Service.

Material corporate events include:

- Entry or Termination of a Material Definitive Agreement
- Completion of Acquisition or Disposition of Assets, Including but not Limited to mergers
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of an Issuer
- Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
- Costs Associated with Exit or Disposal Activities
- Material Impairments
- Sales of Equity Securities
- Material Modification to Rights of Security Holders
- Changes in Issuer's Certifying Accountant
- Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
- Changes in Control of Issuer
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Amendments to the Issuer's Code of Ethics, or Waiver of a Provision of the Code of Ethics
- Other events the issuer considers to be of importance

## OTC Pink Basic Disclosure Guidelines

### 1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Ascendant Solutions, Inc.

### 2) Address of the issuer's principal executive offices

#### Company Headquarters

Address 1: 16250 Knoll Trail Dr. Suite 102, Dallas TX 75248

Address 2:

Address 3:

Phone: 972-250-0945

Email: mheil@ascendantsolutions.com

Website(s): ascendantsolutions.com

#### IR Contact

Address 1: 14651 Dallas Parkway, Suite 800, Dallas TX 75254

Address 2:

Address 3:

Phone: 972-458-8000

Email: gdebusk@halliburtonir.com

Website(s): halliburtonir.com

### 3) Security Information

Trading Symbol: ASDS

Exact title and class of securities outstanding: Common Stock

CUSIP: 04349Y107

Par or Stated Value: \$0.0001

Total shares authorized: 50,000,000 as of: 6/30/15

Total shares outstanding: 21,827,596 as of: 6/30/15

Additional class of securities (if necessary): N/A

Trading Symbol:

Exact title and class of securities outstanding:

CUSIP:

Par or Stated Value:

Total shares authorized: as of:

Total shares outstanding: as of:

#### Transfer Agent

Name: Securities Transfer Corporation

Address 1: 2591 Dallas Parkway Suite 102, Frisco TX 75034

Address 2:

Address 3:

Phone: 469-633-0101

Is the Transfer Agent registered under the Exchange Act?\* Yes:  No:

\*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security: None

Describe any trading suspension orders issued by the SEC in the past 12 months: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On August 5, 2014, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired Family Pharmacy ("Family"), located in Lewisville, Texas and combined Family's operations with Dougherty's Pharmacy location at Forest Park Medical Center.

On September 3, 2014, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired Thrifty Health and Compounding Pharmacy ("Thrifty"), located in Humble, Texas.

On December 10, 2014 the Company issued a special 1 percent common stock dividend.

On January 5, 2015, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired McCrory's Pharmacy ("McCrory's"), located in El Paso, Texas.

On June 27, 2015, Ascendant Solutions, Inc. through its Healthcare subsidiary, Dougherty's Holdings, acquired Medicine Shoppe pharmacy ("McAlester"), located in McAlester, Oklahoma.

#### 4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

- A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.); None
- B. Any jurisdictions where the offering was registered or qualified; None
- C. The number of shares offered; None
- D. The number of shares sold; None
- E. The price at which the shares were offered, and the amount actually paid to the issuer; None
- F. The trading status of the shares; None and
- G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.  
30,000 Restricted Stock Units issued November 13, 2014 to directors  
\$.0001 per share dividend to stockholders of record on December 1, 2014 resulting in 216,086 new shares  
10,000 Restricted Stock Units issued April 15, 2014 to an officer

#### 5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

The Company's financial statements for the period ended June 30, 2015, including (A) Consolidated Balance Sheets as of June 30, 2015 and December 31, 2014, (B) Statements of

Operations for the three months ended June 30, 2015 and June 30, 2014 and for the six months ended June 30, 2015 and June 30, 2014 (C) Statements of Cash Flows for the six months ended June 30, 2015 and June 30, 2014 can be reviewed in the “Quarterly Report-June 30 2015 Financial Statements” that was posted to [otciq.com](http://otciq.com) on August 25, 2015.

(D) Notes to Financial Statements:

### **1. Basis of Presentation**

The interim consolidated financial statements of Ascendant Solutions, Inc. (“Ascendant” or the “Company”) for the period ended June 30, 2015 have not been audited by our independent registered public accounting firm. The December 31, 2014 balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The interim consolidated financial statements and notes thereto should be read in conjunction with the financial statements and notes included in the audited consolidated financial statements for the year ended December 31, 2014. In the opinion of management, these interim financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim periods presented.

Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current year presentation.

### **2. Investment**

The estimated value of the investment in CRESA Partners of Orange County, L.P, “CPOC”, of \$5,107,000 as of June 30, 2015 and December 31, 2014, is accounted for under the cost method of accounting. CPOC is located in Newport Beach, California and provides performance based corporate real estate advisory services to corporate clients around the United States, such as tenant representation services to commercial and industrial users of real estate.

### **3. Deferred Tax Asset**

Significant components of the net deferred tax assets at December 31 are as follows:

<b>Current deferred income tax assets:</b>	
Allowance for doubtful accounts	\$ 10,000
Inventory reserves	28,000
Accrued liabilities	<u>23,000</u>
Net current deferred income tax assets	61,000
Valuation allowance	<u>(61,000)</u>
	<u>\$ -</u>
<b>Non-current deferred income tax assets:</b>	
Net operating loss carryforward	\$ 14,331,000
Alternative minimum tax credit	216,000
Other	<u>78,000</u>
	<u>14,625,000</u>
<b>Non-current deferred income tax liabilities:</b>	
Property and equipment	<u>(85,000)</u>
Net non-current deferred income tax assets	14,540,000
Valuation allowance	<u>(11,540,000)</u>
Net non-current deferred income tax asset	<u>\$ 3,000,000</u>

As of December 31, 2014, the Company had approximately \$216,000 of alternative minimum tax credits available to offset future federal income taxes. The credits have no expiration date. The Company also has unused operating loss carryforwards of \$42,151,000, which expire between 2020 and 2032.

#### **4. Notes Payable**

Notes payable consist of the following:

	<u>June 30, 2015</u>	<u>Dec 31, 2014</u>
<b>First National Bank Southwest Credit Facility, secured by certain retail pharmacy assets</b>		
Revolving line of credit in the principal amount of \$3,200,000, interest at LIBOR plus 3.25% (3.44% at March 31, 2015) payable monthly, matures August 2015.	\$ 2,314,000	\$ 1,672,000
<b>Cardinal Health Term Note, secured by certain retail pharmacy assets</b>		
Term note in the principal amount of \$1,500,000 with interest payable at a bank's prime rate plus 2.75% per annum (6% at June 30, 2015), payable monthly in installments of \$17,861 plus interest, a final payment of \$446,533 plus all accrued and unpaid interest due in full on February 17, 2017.	768,000	875,000
Term note in the principal amount of \$1,827,850 with interest payable at 5.85% per annum payable in monthly installments \$15,232 plus interest, a final payment of \$929,157 plus all accrued and unpaid interest due in full on July 10, 2020.	1,828,000	-
Term note in the principal amount of \$1,241,350 with interest payable at 5.85% per annum payable in monthly installments \$10,344 plus interest, a final payment of \$638,850 plus all accrued and unpaid interest due in full on January 10, 2020.	1,179,000	-
Term note in the principal amount of \$305,350 with interest payable at 5.65% per annum payable in monthly installments \$2,545 plus interest, a final payment of \$155,220 plus all accrued and unpaid interest due in full on August 10, 2019.	277,000	293,000
Term note in the principal amount of \$168,350 with interest payable at 5.85% per annum payable in monthly installments \$2,004 plus interest, a final payment of \$50,356 plus all accrued and unpaid interest due in full on September 10, 2019.	148,000	160,000
Prebate of monthly source rebate	657,000	-
<b>Acquisition Notes Payable , unsecured</b>		
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through June 2018.	478,000	52,000
<b>Insurance notes payable, secured by the respective insurance policies</b>		
Notes payable for the Company's insurance policy premiums with varying monthly payments due through September 2015. Interest rates vary up to 3.06%	31,000	131,000
<b>Equipment notes payable, secured by the respective equipment</b>		
Notes payable for equipment purchased with varying monthly payments due through May 2016. Interest at 9.88%	21,000	28,000
	7,701,000	3,211,000
<b>Less current portion</b>	(788,000)	(451,000)
	<u>\$ 6,913,000</u>	<u>\$ 2,760,000</u>

## **5. Commitments and Contingencies**

### *Guarantee*

The Company remains a co-guarantor on a related party's promissory note with a bank that is secured with collateral.

### *Legal Proceedings*

The Company is occasionally involved in other claims and proceedings, which are incidental to its business. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

## **6) Describe the Issuer's Business, Products and Services**

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations:

Ascendant Solutions, Inc. ("Ascendant") is a value oriented investment firm focused on successfully acquiring, managing and growing community based pharmacies in the Southwest Region.

Date and State (or Jurisdiction) of Incorporation: August 22, 2000 Delaware

- B. the issuer's primary and secondary SIC Codes; 6799 (Investors) 5912 (Drug Stores)

- C. the issuer's fiscal year end date; Calendar Year

- D. principal products or services, and their markets:

Ascendant Solutions, Inc. is a value-oriented investment firm focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Ascendant currently has approximately \$42 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Ascendant at OTCMarkets.com or at [www.ascendantsolutions.com](http://www.ascendantsolutions.com).

## **7) Describe the Issuer's Facilities**

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Dougherty's Retail Pharmacy located at 5959 Royal Lane, Dallas Texas 75230. Approx. 13,000 sq ft leased  
Dougherty's Retail Pharmacy located at 11970 N. Central Expy, Dallas Texas 75243. Approx. 6,000 sq ft leased  
Dougherty's Retail Pharmacy located at 211 FM1960 Bypass Rd East, Humble, TX 77338. Approx. 3,000 sq ft leased

Dougherty's Retail Pharmacy located at 6151 Dew Dr. Ste. 100, El Paso, TX. 79912. Approx. 3,000 sq ft leased  
Dougherty's Retail Pharmacy located at 622 E Wyandotte Ave, McAlester, OK 74501. Approx. 3,000 sq ft leased

Corporate and Real Estate Advisory Services offices located at 16250 Knoll Trail Drive, Suite 102, Dallas Texas 75248.  
Approx. 3,000 sq ft leased

## **8) Officers, Directors, and Control Persons**

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

James C. Leslie, Chairman of the Board  
Mark Heil, President and Chief Financial Officer  
Will Cureton, Director  
Anthony LeVecchio, Director  
Curt Nonomaque, Director

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:
1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); none
  2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; none
  3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; none or
  4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities. none
- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders. none

## **9) Third Party Providers**

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

### Legal Counsel

Name:

Firm: Winstead PC

Address 1: 2728 N. Harwood Street Dallas, Texas 75201

Address 2:

Phone: 214-745-5400

### Accountant or Auditor

Name:  
Firm: BKD, LLP  
Address 1: 14241 Dallas Pkwy #1100 Dallas, TX 75254  
Address 2:  
Phone: (972) 702-8262

Investor Relations Consultant

Name:  
Firm: Halliburton Investor Relations & Communications  
Address 1: 14651 Dallas Pkwy #800 Dallas, TX 75254  
Address 2:  
Phone: (972) 458-8000

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

Name: None

**10) Issuer Certification**

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Mark S. Heil certify that:

1. I have reviewed this Annual Disclosure Statement of Ascendant Solutions, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 25, 2015

/s/ Mark Heil

President and Chief Financial Officer